AWARDDELIVERY ORDEROther than small business
Delivery order 75N91023F00003THE INSTITUTE FOR CANCER RESEARCH
Overview
Award facts
- Net obligations
- $1.20M
- $1,199,274of $1.20M potential value
- Outlays (paid to date)
- $1.11M
- $1.11M paid of $1.20M obligated$1,108,165
- Period of performance
- May 3, 2023 to May 2, 2027
- Ends in 5 months
- Modifications
- 1
- Latest action Apr 7, 2026
- Contract type
- Delivery order
- PIID 75N91023F00003
Contract value is the most the government could spend; obligations are what it has legally committed; outlays are what it has actually paid.
Description of requirement
PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS TASK ORDER TITLE: SULFORAPHANE FOR THE PREVENTION OF MALIGNANT MESOTHELIOMA
Dates and value
- Award date
- Signed on May 1, 2023
- Current value
- $1,199,274Base and exercised options
- Potential value (if all options are exercised)
- $1,199,274
- Parent contract vehicle
- 75N91019D00022 (IDC, multiple award) — 6 orders recorded under it
Obligations by fiscal year of action
- FY2023: $1,199,274
Total across 1 fiscal year: $1,199,274
Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Apr 7, 2026. View on USAspending · Recipient on SAM.gov
Recipient
LocationPHILADELPHIA, PA
UEIFF1XVJMDYVR1
CAGE code1RAF4
Business sizeOther than small businessSize at award, per the contracting officer
Organization typeCorporate tax exempt
Parent companyTHE INSTITUTE FOR CANCER RESEARCH
Business types and certifications
Nonprofit organizationTax-exempt corporation
Self-reported at the time of the action.
Agency and place
Awarding and funding
- Awarded by
- Funded by
- Department of Health and Human Services
- National Institutes Of Health
- NIH NCI
- Funded from
- National cancer institute (0849)Program activities075-0849Federal accounts (agency financial reports)
Place of performance
- Place of performance
- Philadelphia, Pennsylvania 19111-2434
- Congressional district (place of performance)
- PA-02As reported at the time of the action
Classification and competition
Classification
- Product or service (PSC)
- AN12HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (research and development)
Competition
- Extent competed
- Full and open competitionA
- Solicitation procedures
- Subject to multiple award fair opportunityMAFO
- Set-aside
- Not reported
- Contract pricing
- Firm fixed priceJ
- Offers received
- 1
Solicitation and notices
- Solicitation ID
- TORFP 2023 E-01(as reported)
- Solicitation date
- Jan 5, 2023
Contract details
- Subcontracting plan
- Individual subcontract planF
- Major program
- Prevent preclinical drug development program: preclinical efficacy and intermediate biomarkers
- Cost Accounting Standards clause
- Yes - CAS clause includedY
- Certified cost or pricing data
- Yes
- Service Contract Act labor standards
- No
- Commercial procedures
- Commercial products/services procedures not usedD
- Government-furnished property
- Transaction does not use GFE/GFPN
- Bundled requirement
- Not bundledH
- Consolidated requirement
- Not consolidatedD
- Undefinitized action (terms not final)
- No
- Multi-year contract
- No
- Performance-based service acquisition
- No - service where PBA is not used.N
Transaction history
Modification history
- Base award
- May 1, 2023Base obligation at award: $1,199,274
- Latest action
- Apr 7, 2026 — Supplemental agreement (within scope)Modification P00001
- Latest substantive action
- Apr 7, 2026 — Supplemental agreement (within scope)Modification P00001
- Actions by type
- Base award1
- Supplemental agreement (within scope)1
All contract data
All contract data
Every other field reported for this award, as of its latest reported action
Competition
- Evaluation preference
- No preference used
- Local area set-aside
- No
- Synopsized publicly (SAM.gov / FedBizOpps)
- Yes
- Simplified procedures for commercial items
- No
- A-76 (FAIR Act) action
- No
Pricing and financing
- Paid by purchase card
- No
Socio-economic and policy
- Inherently governmental functions
- Other functionsOT
- Recovered materials and sustainability
- No clauses included and no sustainability includedC
- EPA-designated product
- Not requiredE
- Clinger-Cohen Act planning (IT)
- No
- Walsh-Healey Act (materials and supplies)
- No
- Construction wage rates (Davis-Bacon)
- No
Place and origin
- Domestic or foreign entity
- U.S. owned businessA
- Country of product or service origin
- United statesUSA
- Place of manufacture
- Not a manufactured end productC
Structure
- Award or IDV
- Award
- Award type
- Delivery orderC
- Parent vehicle type
- IDCB
- Parent vehicle: multiple or single award
- Multiple awardM
- Parent vehicle agency
- National Institutes Of Health7529
- Awarding agency code
- 7500
- Awarding sub-tier code
- 7529
- Contracting office code
- 75N910
- Transactions recorded under this award key
- 2
Funding
- Funding agency code
- 7500
- Funding sub-tier code
- 7529
- Funding office code
- 75N910
- Treasury accounts
- 075-2023/2023-0849-000
- Object classes
- 25.5: Research and development contracts
- Disaster or emergency funding (DEFC)
- Q: Not Designated Nonemergency/Emergency/Disaster/Wildfire Suppression